Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AMRX compared with JXN: revenue, margins and what each company keeps, and the suppliers and customers both name
AMRX
Amneal Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
JXN
Jackson Financial Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
AMRX
Amneal Pharmaceuticals, Inc.
vs
JXN
Jackson Financial Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
JXN: latest quarter not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only AMRX
14
—
Customer A
unlisted
customer
—
Kashiv Biosciences
unlisted
supplier
—
ApiJect Systems
unlisted
supplier
—
BIAL-Portela & Ca
unlisted
supplier
10 more · AMRX chain
›
Shared
0
No disclosed counterparties: JXN.
Only JXN
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AMRX, solid
JXN, dashed
AMRX
Amneal Pharmaceuticals, Inc.
Change
21.50
▲
+0.70%
· post 21.43
Mkt cap
$6.9B
Revenue
$796M
Q2 FY26
Revenue
$3.0B
FY25
JXN
Jackson Financial Inc.
Change
134.76
▼
−0.89%
· post 134.79
Closed
Oct 30 '26
Mkt cap
$9.1B
Revenue
$2.8B
Q2 FY26
Revenue
$10.5B
FY25
vs
Compare
Closed
Oct 30 '26
AMRX
Amneal Pharmaceuticals, Inc.
vs
JXN
Jackson Financial Inc.
21.50
▲
+0.70%
post 21.43
Price
134.76
▼
−0.89%
post 134.79
$6.9B
Mkt cap
$9.1B
Q2 FY26
$796M
Revenue
$2.8B
Q2 FY26
FY25
$3.0B
Revenue
$10.5B
FY25
Change
Change
AMRX
21.50
▲
+0.70%
vs
JXN
134.76
▼
−0.89%
Closed
Oct 30 '26